Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Verrica Pharmaceuticals (VRCA)
NASDAQ:VRCA
RESEARCH TOOLSreports
Holding VRCA?
Track your performance easily
VRCA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.86 - $11.41
Previous Close$8.52
Volume138.81K
Average Volume (3M)220.65K
Market Cap
$361.42M
Enterprise Value$358.96M
Total Cash (Recent Filing)$48.90M
Total Debt (Recent Filing)$46.44M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Aug 07, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding42,420,053
10 Day Avg. Volume193,499
30 Day Avg. Volume220,645
Standard Deviation0.28
R-Squared0.11
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)186.25
Price to Sales (P/S)158.97
Price to Cash Flow (P/CF)-4.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue40.27
Enterprise Value/Gross Profit81.99
Enterprise Value/Ebitda-13.26
Forecast
1Y Price Target
$14.20Price Target Upside69.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Verrica Pharmaceuticals News
PremiumCompany Announcements
Verrica Pharmaceuticals: Financial Struggles Amid Strategic Shifts
PremiumCompany Announcements
Verrica Pharmaceuticals Undergoes Leadership and Financial Restructuring
PremiumCompany Announcements
Verrica Pharmaceuticals Strives for Nasdaq Compliance
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $2.86 and its highest was $11.41 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Currently, no data Available
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Aug 07, 2024 which is 90 days ago.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on May 13, 2024. The company reported -$0.44 earnings per share for the quarter, beating the consensus estimate of -$0.447 by $0.007.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -$0.41.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 42,420,050 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.44 in its last earnings report, beating expectations of -$0.447. Following the earnings report the stock price went up 19.5%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Among the largest hedge funds holding Verrica Pharmaceuticals’s share is Perceptive Advisors LLC. It holds Verrica Pharmaceuticals’s shares valued at 42M.
---
Verrica Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.20 (69.65% Upside)
$14.20 (69.65% Upside)
Blogger Sentiment
Bullish
VRCA Sentiment 100%
Sector Average 71%
Sector Average 71%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 1.0%
Last 30 Days ▼ 1.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.29%
12-Months-Change
Fundamentals
Return on Equity
-243.34%
Trailing 12-Months
Asset Growth
-3.39%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals, Inc. operates as a clinical-stage medical dermatology company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its lead product VP-102, is a proprietary topical therapy used in common skin indications including Molluscum contagiosum and Verruca Vulgaris. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.
---
VRCA Earnings Call
Q1 2024
0:00 / 0:00
---
VRCA Stock 12 Month Forecast
Average Price Target
$14.20
▲(69.65% Upside)
Technical Analysis
Bausch Health Companies
―
Eagle Pharmaceuticals
―
Heron Therapeutics
―
Kala Pharmaceuticals
―
Best Analysts Covering VRCA
1 Year
1 Year Success Rate
17/31 ratings generated profit
1 Year Average Return
+14.17%
reiterated a buy rating 6 months ago
Copying Oren Livnat's trades and holding each position for 1 Year would result in 54.84% of your transactions generating a profit, with an average return of +14.17% per trade.
---